Acute fatty liver of pregnancy (AFLP) is a rare and potentially fatal disorder that usually manifests in the third trimester or even sometimes after delivery. Anesthesiologists are an important part of the multidisciplinary team involved in the management of such patients during their perioperative care and as well as in the intensive care unit (ICU). AFLP usually manifests with deranged liver and renal function tests and episodes of hypoglycemia. The diagnosis is typically clinical. Prompt delivery and supportive care in ICU are the cornerstone of treatment. We, hereby, describe the successful management of the patient with postpartum AFLP in ICU.

Key words: Acute fatty liver, Hypoglycemia, Intensive care unit, Pregnancy

Acute fatty liver of pregnancy (AFLP) is a rare and potentially fatal disorder with an incidence of 1–3 cases per 10,000 pregnancies [1]. AFLP is an obstetric emergency that usually develops in the third trimester of pregnancy or early postpartum period. It is characterized by acute hepatic failure secondary to fatty infiltration of the liver. The spectrum of disease can range from mild symptoms to gross derangements.

This case report describes the successful management of a pregnant female who developed AFLP in the postpartum period and was managed in the intensive care unit (ICU). This case highlights the importance of vigilant monitoring that can help detect this fatal disease, and hence, early intervention can save precious lives.

CASE REPORT

A 22-year-old full-term primigravida presented to the emergency with complaints of altered sensorium and an episode of seizure in the morning. The patient had a history of mild abdominal pain, nausea, and headache for 2 days. There was no other significant medical, surgical, or obstetric history.

On admission, her vitals were blood pressure (BP) – 180/120 mm of Hg, heart rate – 88/min, and saturation of arterial blood (SPO2) of 94%. She was afebrile. There was no jaundice or icterus at presentation. Fetal heart sounds were present.

Ultrasonography (USG) showed a single viable fetus. Laboratory investigations showed deranged liver function tests (LFTs), deranged renal functional tests (RFTs), and leukocytosis (Table 1). There were traces of proteins in the urine. The patient was irritable.

The emergency lower section caesarian section (LSCS) was done under general anesthesia (GA) with a presumptive diagnosis of eclampsia. The intraoperative period was uneventful. A live female child was born with an APGAR score of 3 and was shifted immediately to the neonatal ICU in an intubated state. The patient was shifted to ICU in an intubated state in view of preoperative altered mental status, deranged LFTs, poor respiratory efforts, and arterial blood gas analysis showing pH 7.288, partial pressure of carbon dioxide (pCO2) 18.2 mm Hg, partial pressure of oxygen (pO2) 208.3 mm Hg, bicarbonate 8.7 meq/L, and base excess 15.8 meq/L.

On ICU arrival, her vitals were BP 150/100, pulse rate 98 /min, and SpO2 100% on a ventilator. Her vitals remained stable during her stay in ICU without any inotropic support. Mechanical ventilation was initiated on synchronized intermittent mandatory ventilation mode with tidal volume – 350 ml, FiO2 – 40%, pressure support 12, and positive end-expiratory pressure of 5. Sedation and analgesia were ensured with midazolam and fentanyl infusions. Medicine and neurology consultations were taken.

Computer tomography of the head and magnetic resonance imaging of the brain was done to rule out any intracranial bleed. Repeat USG abdomen showed normal-sized liver with raised echotexture suggesting fatty infiltration (Fig. 1). Her LFTs and RFTs deteriorated further during her stay in ICU post-LSCS (Table 1). Urine output also started decreasing. The coagulation profile also showed derangement (Table 1), for which 4 units of fresh frozen plasma (FFP) were transfused.
In ICU on the 2nd post-operative day, the patient had frequent episodes of decreased consciousness/stare look which correlated well with hypoglycemia (blood glucose 40 mg/dl or below) and which responded to dextrose infusions. The patient was treated with a 25% Dextrose infusion, followed by continuous dextrose 10% infusion with RBS monitoring.

The patient gradually improved with supportive care in the ICU, including broad-spectrum antibiotics, fluid support, mechanical ventilation, and correction of complications like hypoglycemia. The patient was gradually weaned off from the mechanical ventilation within 48 h, postoperatively. The LFTs and RFTs started improving from day 4 in ICU and the patient was shifted from ICU to ward after 8 days in hemodynamically stable condition.

**DISCUSSION**

AFLP was first described in 1934 by Stadder and Cadden as acute yellow atrophy of the liver. It was thought to be a variant of preeclampsia. With the advancement in diagnostic techniques, early reorganization and differential from other liver disorders of pregnancy are now possible. More advanced multidisciplinary care has now resulted in the maternal mortality rate to be 7–18% and the fetal mortality rate 9–23% [2]. AFLP usually presents between the 30th and 38th weeks of gestation. However, there are a few reported cases of AFLP in the second trimester [3].

The precise pathogenesis of AFLP is not clear, a proposed hypothesis is an accumulation of free fatty acids in the liver due to inadequate activity of mitochondrial long-chain 3-hydroxyacyl CoA dehydrogenase [4]. Another theory of fetal fatty acid oxidation disorders is also linked with the pathogenesis of AFLP [1]. Scott Rector et al. have first to report the association between recurrent maternal AFLP with a fetal fatty acid oxidation disorder in two siblings who both died at 6 months of age [5].

Maternal hepatotoxicity and mitochondrial dysfunction occur secondary to the accumulation of hepatotoxic long-chain fatty acid metabolites which had crossed the placental barrier and have reached the maternal side of the circulation. High levels of free fatty acids increase the reactive oxygen species, caspase activity, and hence induce apoptosis [6]. Another common finding in these patients is fatty infiltration of other organs as well. It is more common in females with multiple pregnancies and lower body mass index.

It usually presents as non-specific symptoms of nausea, malaise, vomiting, headache, epigastric pain, and jaundice, leading to rapidly developing severe liver dysfunction, disseminated intravascular coagulation, hypoglycemia, and hepatic encephalopathy. Due to its variable presentation, diagnosis is usually delayed or missed or confused with other hepatic disorders of pregnancy (Table 2) [2]. Other hepatic disorders that need to be considered include are not limited to obstetric cholestasis, HELLP syndrome, preeclamptic liver dysfunction, and hyperemesis gravidarum with liver dysfunction (Table 2).

AFLP is typically a clinical diagnosis made on the basis of SWANSEA criteria (Table 3). Confirmatory diagnosis is by liver biopsy which shows swollen pale hepatocytes and intrahepatic fat lobules. However, the liver biopsy is rarely performed due to risks associated with the procedure [1].

Management of AFLP is usually supportive and similar to that of hepatic failure from other causes. A recent UK-wide Obstetric Surveillance System study also suggests that management is now improving, with 60% of women with AFLP are admitted in ICU, and mortality is <2% or 5 cases/1 lac in their case series of 57 patients [7]. Prompt delivery is recommended to avoid maternal deterioration and intrauterine death. Supportive care, including fluid management, maintenance of glucose levels, and correction

---

**Table 1: Sequential investigations of the patient**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Before delivery</th>
<th>ICU day 1</th>
<th>ICU day 2</th>
<th>ICU day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>11.5</td>
<td>9.8</td>
<td>10.2</td>
<td>10.1</td>
</tr>
<tr>
<td>Total leukocyte count (cells/ml3)</td>
<td>15,300</td>
<td>13,800</td>
<td>12,100</td>
<td>10,500</td>
</tr>
<tr>
<td>Platelets (cells/µl)</td>
<td>151,000</td>
<td>208,000</td>
<td>210,000</td>
<td>215,000</td>
</tr>
<tr>
<td>Blood urea (mg/dl)</td>
<td>103</td>
<td>123</td>
<td>122</td>
<td>94</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>4.3</td>
<td>4.3</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Total/direct bilirubin (mg/dl)</td>
<td>0.8/0.3</td>
<td>1.0/0.5</td>
<td>0.4/0.1</td>
<td>0.4/0.1</td>
</tr>
<tr>
<td>Aspartate aminotransferase (IU/L)</td>
<td>241</td>
<td>372</td>
<td>377</td>
<td>80</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/L)</td>
<td>171</td>
<td>301</td>
<td>384</td>
<td>98</td>
</tr>
<tr>
<td>Alkaline phosphatase (IU/L)</td>
<td>450</td>
<td>453</td>
<td>448</td>
<td>297</td>
</tr>
<tr>
<td>Prothrombin time/INR</td>
<td>86.6/1.17</td>
<td>80/1.5</td>
<td>70/1.7</td>
<td>92.8/1.08</td>
</tr>
</tbody>
</table>

Viral markers: Non-reactive

---

**Figure 1: Ultrasonogram showing raised echotexture of the liver**

---

Vol 6 | Issue 10 | October 2020  
Indian J Case Reports 561
Acute fatty liver of pregnancy (AFLP) and anesthetic

Table 2: Different hepatic disorders of pregnancy [2]

<table>
<thead>
<tr>
<th>HELLP syndrome</th>
<th>Obstetric cholestasis</th>
<th>Preeclamptic liver dysfunction</th>
<th>Hyperemesis gravidarum with liver dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated aspartate aminotransferase level (&gt;70 U/L)</td>
<td>Pruritus</td>
<td>Elevated liver enzyme or bilirubin level</td>
<td>Elevated liver enzyme or bilirubin level</td>
</tr>
<tr>
<td>Low platelet count (&lt;100 × 10^9/L)</td>
<td>Low acid levels in the second or third trimester</td>
<td>Hypertension</td>
<td>Persistent vomiting, &gt; 1 week</td>
</tr>
<tr>
<td>Hemolysis (lactate dehydrogenase level &gt;600 U/L)</td>
<td></td>
<td>Proteinuria, after 20 weeks of gestation</td>
<td>during first or second trimester</td>
</tr>
</tbody>
</table>

Table 3: SWANSEA criteria for the diagnosis of acute fatty liver of pregnancy, six or more of the following findings are required in the absence of another cause

1. Vomiting
2. Abdominal pain
3. Polydipsia/polyuria
4. Encephalopathy
5. Elevated bilirubin >14 µmol/l
6. Hypoglycemia <4 mmol/l
7. Elevated uric acid >340 µmol/l
8. Leukocytosis >11×10^9/L
9. Ascites or bright liver on ultrasound scan
10. Elevated transaminases (AAT or ALT) >42 IU/l
11. Elevated ammonia >47 µmol/l
12. Renal impairment: Creatinine >150 µmol/l
13. Coagulopathy: Prothrombin time >14 s or APPT >34 s
14. Microvesicular steatosis on liver biopsy

of coagulopathy, is required. Sepsis usually occurs in 50% of patients and is a major cause of morbidity and mortality. Hence, prophylactic antibiotics are needed. Vitamin K and FFP may be needed if coagulopathy ensues. AFLP is usually self-limiting, but rarely liver transplantation may be needed if a fulminant hepatic failure occurs. Future pregnancies should be discussed, including the risk of recurrence as few reports have been reported in the literature [8]. In severe form, it can be fatal. Ziki et al. reported a case of 18-year-old primigravida who developed AFLP. Despite the best possible efforts, she deceased in the third postpartum day [9]. In some cases, it was preceded by intrahepatic cholestasis of pregnancy. English and Rao reported a case of a 33-year-old woman who presented with pruritus at 34 weeks gestation. A diagnosis of intrahepatic cholestasis of pregnancy was made based on elevated bile acids and elevated liver transaminases. However, postnatally, she developed AFLP [10].

The use of regional anesthesia for labor and cesarean is often debated due to the risk of a rapid deterioration of coagulopathy and the potential risk of a spinal or epidural hematoma. GA poses risks due to hepatic dysfunction, worsening intracranial pressures, and higher risk associated with airway management. Volume replacements and electrolyte imbalances are to be corrected preoperatively. Blood products are kept ready as per hematological investigations. Coadministrations of adjuncts like tranexamic acid can be needed. Careful and close monitoring of hemodynamics is mandatory with judicious use of central line, arterial lines, and vasopressors, or even cerebral vasodilators if needed. A decision needs to be individualized depending on the presenting symptoms, investigations available, and in consultation with the obstetric team.

CONCLUSION

AFLP is an underdiagnosed disease and should be kept in the differential diagnosis of pregnant females with deranged liver and renal function tests, especially with episodes of hypoglycemia. Early detection with advances in critical care management has changed AFLP from being a highly fatal complication to a treatable entity.

REFERENCES